Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report

Figure 3 Clonal evolution architecture of the patient. The patient was initially found to have del(5q) with EGR1 gene deletion, so she was diagnosed with MDS (low risk). Following lenalidomide treatment, the patient developed inv(3) with overexpression of EVI1. At that time, the patient's diagnosis was revised to MDS (very high risk). In addition, the patient also had ASXL1 mutations. The revised international prognostic scoring system (IPSS-R) for myelodysplastic syndrome was calculated according to a previously reported method[24], and the details can be found in Supplementary Table 1. HB: Haemoglobin; PLT: Platelet; IPSS-R: Revised International Prognostic Scoring System.